The SU.VI.MAX and SU.VI.MAX 2 studies were approved by the Ethics Committee for Studies with Human Subjects of the Paris-Cochin Hospital (CCPPRB nos. 706 and 2364, respectively) and the Commission Nationale Informatique et Liberté (CNIL nos. 334641 and 907094, respectively). Written informed consent was obtained from all participants. Clinical Trial Registration at clinicaltrial.gov (number NCT00272428).